Furazolidone

Furazolidone is a monoamine oxidase (MAO) inhibitor with antiproliferative, apoptosis-inducing and differentiation-promoting activities. Furazolidone may inhibit leukemia fusion protein-mediated bone marrow transformation by upregulating the stability of the tumor suppressor protein p53. Furazolidone exhibits anti-leukemic activity in acute myeloid leukemia (AML) cell lines and can be used for anti-AML research[1][2].

Product Specifications

CAS Number

[67-45-8]

UNSPSC

12352005

Hazard Statement

H361

Target

Antibiotic; Apoptosis; Bacterial; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/Furazolidone.html

Purity

99.87

Solubility

DMSO : 5.56 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1OCCN1/N=C/C2=CC=C([N+]([O-])=O)O2

Molecular Formula

C8H7N3O5

Molecular Weight

225.16

Precautions

H361

References & Citations

[1]Jiang X, et al. A novel application of furazolidone: anti-leukemic activity in acute myeloid leukemia. PLoS One. 2013 Aug 9;8 (8) :e72335.|[2]Ma S, et al. Furazolidone Increases Survival of Mice Exposed to Lethal Total Body Irradiation through the Antiapoptosis and Antiautophagy Mechanism. Oxid Med Cell Longev. 2021 Feb 4;2021:6610726.